Host-cell enzymes vital for inhibiting mutant forms of coronavirus, study finds

Host-cell enzymes called PARP12 and PARP14 are important for inhibiting mutant forms of a coronavirus, according to a study published May 16 in the open-access journal PLOS Pathogens by Stanley Perlman of the University of Iowa, Anthony Fehr of the University of Kansas, and colleagues.

A biochemical process called ADP-ribosylation facilitates the host response to virus infection. This process is catalyzed by enzymes called poly(ADP-ribose) polymerases (PARPs). Several viruses, including all members of the coronavirus family, which cause severe disease in agriculturally important and companion animals as well as humans, encode a macrodomain to reverse ADP-ribosylation and combat this immune response, facilitating viral replication and virulence. As such, viruses with mutations in the macrodomain are highly attenuated and cause minimal disease in organisms. These results suggest that macrodomains counter cellular ADP-ribosylation, but the potential role of PARPs in this process has not been clear.

In the new study, the authors used macrophage cells and mice infected with a coronavirus to identify PARPs, specifically PARP12 and PARP14, as host-cell ADP-ribosylating enzymes important for the attenuation of macrodomain-mutant viruses. The findings showed that the macrodomain is required to prevent PARP-mediated inhibition of coronavirus replication, and enhancement of the production of antiviral proteins called interferons. According to the authors, the results demonstrate a broad strategy of virus-host interactions, unveil previously unknown mechanisms of immune regulation, and indicate that the macrodomain may be a useful target for antiviral therapy.

The authors add:

ADP-ribosylation has increasingly been recognized as a host cell strategy to combat virus infections and viruses have learned how to counter this modification. Here we describe a previously unidentified interaction between the specific host cell enzymes that effect ADP-riboslylation and a viral protein that evades this host response.”

Source:

PLOS

Journal reference:

Grunewald, M.E. et al. (2019) The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. PLOS Pathogens. doi.org/10.1371/journal.ppat.1007756

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CAR T cell therapy breakthroughs bring new hope for treating solid tumors